RegeneRx Biopharmaceuticals announced that the FDA has granted its drug candidate, Thymosin beta 4 (Tβ4) Orphan Drug designation for the treatment of neurotrophic keratopathy (NK). Tβ4 is a novel therapeutic peptide being developed for tissue and organ protection, repair, and regeneration.
RELATED: Ophthalmic Disorders Resource Center
Neurotrophic keratopathy is a serious degenerative disease of the corneal epithelium. A reduction in corneal sensitivity or complete corneal anesthesia is the hallmark of this disease and is responsible for producing corneal ulceration, perforation, pain and impaired vision.
RegeneRx currently has three drug candidates in clinical development for ophthalmic (RGN-259), cardiac (RGN-352), and dermal (RGN-137) indications.
For more information call (301) 208-9191 or visit RegeneRx.com.